Literature DB >> 33888584

Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis.

Norihisa Nishimura1, Davide De Battista1, David R McGivern2, Ronald E Engle1, Ashley Tice1, Rafaelle Fares-Gusmao2, Juraj Kabat3, Anna Pomerenke1, Hanh Nguyen1, Shinya Sato1, Kevin W Bock4, Ian N Moore4, David E Kleiner5, Fausto Zamboni6, Harvey J Alter7, Sugantha Govindarajan8, Patrizia Farci9.   

Abstract

Older age at the time of infection with hepatitis viruses is associated with an increased risk of liver fibrosis progression. We hypothesized that the pace of fibrosis progression may reflect changes in gene expression within the aging liver. We compared gene expression in liver specimens from 54 adult donors without evidence of fibrosis, including 36 over 40 y old and 18 between 18 and 40 y old. Chitinase 3-like 1 (CHI3L1), which encodes chitinase-like protein YKL-40/CHI3L1, was identified as the gene with the greatest age-dependent increase in expression in liver tissue. We investigated the cellular source of CHI3L1 in the liver and its function using liver tissue specimens and in vitro models. CHI3L1 expression was significantly higher in livers of patients with cirrhosis of diverse etiologies compared with controls represented by patients who underwent liver resection for hemangioma. The highest intrahepatic CHI3L1 expression was observed in cirrhosis due to hepatitis D virus, followed by hepatitis C virus, hepatitis B virus, and alcohol-induced cirrhosis. In situ hybridization of CHI3L1 messenger RNA (mRNA) identified hepatocytes as the major producers of CHI3L1 in normal liver and in cirrhotic tissue, wherein hepatocytes adjacent to fibrous septa showed higher CHI3L1 expression than did those in more distal areas. In vitro studies showed that recombinant CHI3L1 promotes proliferation and activation of primary human hepatic stellate cells (HSCs), the major drivers of liver fibrosis. These findings collectively demonstrate that CHI3L1 promotes liver fibrogenesis through a direct effect on HSCs and support a role for CHI3L1 in the increased susceptibility of aging livers to fibrosis progression.

Entities:  

Keywords:  CHI3L1; aging; cirrhosis; liver fibrosis

Mesh:

Substances:

Year:  2021        PMID: 33888584      PMCID: PMC8092404          DOI: 10.1073/pnas.2019633118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Fibrosis progression in initially mild chronic hepatitis C.

Authors:  S Boccato; R Pistis; F Noventa; M Guido; L Benvegnù; A Alberti
Journal:  J Viral Hepat       Date:  2006-05       Impact factor: 3.728

Review 2.  Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer.

Authors:  Julia S Johansen
Journal:  Dan Med Bull       Date:  2006-05

3.  Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.

Authors:  Robert J Fontana; Jules L Dienstag; Herbert L Bonkovsky; Richard K Sterling; Deepa Naishadham; Zachary D Goodman; Anna S F Lok; Elizabeth C Wright; Grace L Su
Journal:  Gut       Date:  2010-07-30       Impact factor: 23.059

Review 4.  Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome.

Authors:  H J Alter; L B Seeff
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

5.  Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index.

Authors:  Thomas B Kelleher; Shruti H Mehta; Ramakrishnan Bhaskar; Mark Sulkowski; Jacquie Astemborski; David L Thomas; Richard E Moore; Nezam H Afdhal
Journal:  J Hepatol       Date:  2005-04-25       Impact factor: 25.083

6.  Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

Authors:  T Poynard; P Bedossa; P Opolon
Journal:  Lancet       Date:  1997-03-22       Impact factor: 79.321

7.  Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

Authors:  Jason M Hui; Archana Sud; Geoffrey C Farrell; Priyanka Bandara; Karen Byth; James G Kench; Geoffrey W McCaughan; Jacob George
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

8.  Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Marta Melis; Giacomo Diaz; David E Kleiner; Fausto Zamboni; Juraj Kabat; Jinping Lai; Giulia Mogavero; Ashley Tice; Ronald E Engle; Steven Becker; Charles R Brown; Jeffrey C Hanson; Jaime Rodriguez-Canales; Michael Emmert-Buck; Sugantha Govindarajan; Michael Kew; Patrizia Farci
Journal:  J Transl Med       Date:  2014-08-21       Impact factor: 5.531

9.  Analysis of gene expression data using BRB-ArrayTools.

Authors:  Richard Simon; Amy Lam; Ming-Chung Li; Michael Ngan; Supriya Menenzes; Yingdong Zhao
Journal:  Cancer Inform       Date:  2007-02-04

10.  Chitinase 3-like 1-CD44 interaction promotes metastasis and epithelial-to-mesenchymal transition through β-catenin/Erk/Akt signaling in gastric cancer.

Authors:  Biao Geng; Jinshun Pan; Ting Zhao; Jie Ji; Chen Zhang; Ying Che; Jing Yang; Hui Shi; Juan Li; Hong Zhou; Xianmin Mu; Che Xu; Chao Wang; Yue Xu; Zheng Liu; Hao Wen; Qiang You
Journal:  J Exp Clin Cancer Res       Date:  2018-08-30
View more
  3 in total

1.  Serum sphingosine-1 phosphate level is increased in patients with hepatitis B and displays a positive association with liver fibrosis.

Authors:  Mei Sun; Ling Zeng; Min Hu
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

2.  The Value of Serum CHI3L1 for the Diagnosis of Chronic Liver Diseases.

Authors:  Hanyu Qiu; Xiaomei Zhang
Journal:  Int J Gen Med       Date:  2022-06-28

3.  Hierarchical Hydrogels with Ordered Micro-Nano Structures for Cancer-on-a-Chip Construction.

Authors:  Luyao Zhu; Changmin Shao; Hanxu Chen; Zhuoyue Chen; Yuanjin Zhao
Journal:  Research (Wash D C)       Date:  2021-12-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.